腰痹通胶囊联合塞来昔布胶囊治疗椎间盘源性腰痛的疗效及对血清炎性因子和疼痛介质的影响

摘要 目的：探讨腰痹通胶囊联合塞来昔布胶囊治疗椎间盘源性腰痛（DLBP）的疗效及对血清炎性因子和疼痛介质的影响。方法：选择2017年5月~2022年5月期间我院接收的75例DLBP患者。依据信封抽签法将患者分为对照组（n=37）和研究组（n=38）,对照组接受塞来昔布胶囊治疗,研究组接受腰痹通胶囊联合塞来昔布胶囊治疗。对比两组疗效、临床症状评分、血清炎性因子和疼痛介质的变化情况,同时观察两组用药安全性。结果：研究组痊愈8例,显效10例,有效18例,临床总有效率94.74%,高于对照组的痊愈4例,显效8例,有效17例,临床总有效率78.38%（P<0.05）。治疗1个月后,研究组的视觉疼痛模拟（VAS）评分、Oswestry功能障碍指数（ODI）较对照组更低（P<0.05）,改良日本骨科协会（JOA）评分较对照组更高（P<0.05）。治疗1个月后,研究组的血清白细胞介素-6（IL-6）、C反应蛋白（CRP）、肿瘤坏死因子-α（TNF-α）水平较对照组更低（P<0.05）。治疗1个月后,研究组的血清 P物质（SP）、多巴胺（DA）、前列腺素E₂（PGE₂）水平较对照组更低（P<0.05）。两组不良反应发生率组间对比差异不显著（P>0.05）。结论：腰痹通胶囊联合塞来昔布胶囊治疗DLBP,可有效减轻疼痛,恢复腰椎功能,降低血清炎性因子和疼痛介质水平。     

益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂对COPD稳定期患者肺功能、细胞免疫功能和血清bFGF、SIRT1的影响

摘要 目的：探讨益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂对慢性阻塞性肺疾病（COPD）疾病稳定期患者肺功能、细胞免疫功能和血清碱性成纤维细胞生长因子（bFGF）、沉默信息调节因子1（SIRT1）的影响。方法：纳入我院2021年3月~2022年6月期间收治的COPD稳定期患者104例,按照随机数字表法分为对照组（乌美溴铵维兰特罗吸入粉雾剂治疗,n=52）和观察组（益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂治疗,n=52）。对比两组临床症状恢复时间、6 min步行试验（6MWT）和COPD评估测试（CAT）评分、肺功能[第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、每分钟最大通气量（MVV）]、细胞免疫功能和血清bFGF、SIRT1水平,观察两组不良反应发生情况。结果：与对照组相比,观察组的肺啰音、咳嗽、咯痰消失时间缩短（P<0.05）。与对照组相比,观察组治疗14 d后6MWT更远,CAT评分更低（P<0.05）。与对照组相比,观察组治疗14 d后FVC、FEV₁、MVV更高（P<0.05）。与对照组相比,观察组治疗14 d后CD3⁺、CD4⁺、CD4⁺/CD8⁺更高,CD8⁺更低（P<0.05）。与对照组相比,观察组治疗14 d后bFGF更低,SIRT1更高（P<0.05）。两组不良反应总发生率组间对比无差异（P>0.05）。结论：益肺胶囊联合乌美溴铵维兰特罗吸入粉雾剂有助于调节COPD稳定期患者血清bFGF、SIRT1水平,改善肺功能和细胞免疫功能。     

Protein components of two strains of granulosis virus of the armyworm, Pseudaletia unipuncta (Lepidoptera,Noctuidae)

A synergistic Hawaiian (GVH) and a nonsynergistic Oregonian (GVO) strain of a granulosis virus (GV) infect the armyworm, Pseudaletia unipuncta. The protein components of the enveloped virions and of the capsule (inclusion body) were compared between the two strains. When the enveloped virions of both strains were analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, the protein patterns were similar except for minor peaks in the higher molecular weight region. On the other hand, the capsule proteins differed between the two strains when examined with immunoelectrophoresis and SDS-polyacrylamide gel electrophoresis. The capsule proteins of GVH were composed of two major proteins, one a structural protein and the other the protein of the synergistic factor. The capsule protein of GVO, however, had only the structural protein. The rocket immunoelectrophoresis and affinity chromatography indicated that the structural proteins of the two strains were partially dissimilar. The molecular weight of the structural protein of GVO was 29,100 ± 500 and that of GVH was 28,700 ± 500. The amount of synergistic factor in a GVH capsule was about 5% of the dissolved capsule components.     

Effect of 2-chloroethylphosphonic acid on capsule formation and alkaloid content in Papaver somniferum

Application of different concentrations of ethephon (2-chloroethylphosphonic acid) to Papaver somniferum L. at the times of stem elongation, bud, and capsule formation produced different effects. Ethephon (10^-2 M ) retarded growth of the plant and inhibited capsule formation during stem elongation, significantly reduced capsule size during the flowering period, but did not alter capsule development during capsule formation. When applied during the period of stem elongation, ethephon (10^-3 M and 10^-4 M ) reduced capsule size; alkaloid accumulation was reduced by ethephon at a concentration of 10^-3 M , but slightly increased by 10^-4 M . Ethephon (10^-3 M and 10^-4 M ) did not alter capsule development or alkaloid content significantly when applied during bud formation, but stimulated capsule size and alkaloid content when applied during capsule formation. Pretreating the plants with Ag⁺ (silver nitrate) did not reverse the ethephon effect. The results suggest that capsule maturation and alkaloid accumulation in P. somniferum are modified by ethylene, which is produced as a result of exogenous ethephon treatment.     

Seasonal influence on head capsule deformities in Chironomus zealandicus (Hudson) (Diptera: Chironomidae)

The natural incidence of deformities in the head capsules of Chironomus zealandicus was investigated at four lake sites in the central North Island (New Zealand) in summer (December) of 1994, 1995 and 1996, and winter (June) of 1995 and 1996. Significant differences were observed in deformities between sites and seasons. Individuals from Hamurana Stream, a relatively clean site, had the lowest incidence of deformities. However, there were still significant numbers of deformed chironomids. The incidence of deformity increased in summer in larvae from all sites except Hamurana Stream. No seasonal differences were observed in larvae from Hamurana Stream. There are indications that substrate type, season and genetic factors, as well as sediment chemistry may have collectively contributed to the incidence of head capsule abnormalities in C. zealandicus.     

奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者的临床疗效

目的:探讨奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者的临床疗效。方法:非盲法随机对照方法将患者分成试验组和对照组,各27例。试验组患者使用奥沙利铂联合替吉奥胶囊治疗,对照组患者使用奥沙利铂治疗,均为4个周期。评价两组治疗后的临床疗效和不良反应。结果:试验组:CR 1例,PR 11例,SD 10例,PD 5例。(CR+PR)RR 44.4%。中位疾病进展时间(TTP)9.5个月,中位生存期(MST)19.1个月。对照组:CR 0例,PR 5例,SD 8例,PD 15例。(CR+PR)RR 18.5%。中位疾病进展时间(TTP)8.6个月,中位生存期(MST)16.9个月。主要不良反应为血液毒性、胃肠道反应、外周神经炎及肝功能异常。试验组白细胞下降15例,对照组12例,试验组贫血发生为13例,对照组的为21例,试验组恶心、呕吐发生为18例,对照组为24例,试验组便秘发生为8例,对照组为15例,差异有统计学意义(P0.05)。结论:奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者相比单独使用奥沙利铂更加有效,更具优越性,不良反应更少,患者的生存质量得以改善,值得临床上推广应用。     

苯磺酸左旋氨氯地平片联合脂必泰治疗糖尿病合并冠心病痰瘀交阻证的临床疗效观察

摘要目的：观察苯磺酸左旋氨氯地平片联合脂必泰胶囊治疗糖尿病合并冠心病痰瘀交阻证的临床疗效。方法：120例糖尿病性冠心病痰瘀交阻证患者随机分为两组,均给与注射胰岛素控制血糖。对照组（n=60）给与阿托伐他汀10mg,每日1次口服。治疗组（n=60）给与苯磺酸左旋氨氯地平片5mg,每天1次口服;脂必泰胶囊1粒,每天2次口服。两组均治疗3个月。分析比较治疗前后空腹血糖（FBG）、总胆固醇（TC）等指标,心电图（ECG）,并记录中医症状积分。结果：治疗组总有效率86．67％,对照组总有效率51．67％,两组相比较,差异有显著性（P〈0．01）。两组空腹血糖（VBO）、糖化血红蛋白（HbAlc）、甘油三酯（TO）等指标治疗后与治疗前比较,差异有统计学意义（P〈0．05或P〈0．01）。治疗后治疗组总胆固醇（TC）、高密度脂蛋白（HDL．C）与对照组相比较,变化显著（P〈0．05）。治疗组中医症状积分下降较对照组明显（P〈O．05或P〈0．01）。结论：苯磺酸左旋氨氯地平片联合脂必泰胶囊治疗糖尿病性冠心病痰瘀交阻证疗效确切。     

Detection of cobalt in synovial fluid from metal-on-metal hip prosthesis: correlation with the ion haematic level

Abstract

Hip replacement with large metal-on-metal (MoM) coupling has recently been under attention for its metal ions release, inducing several disorders. Since the blood level toxicity threshold for cobalt is known, the aim of this work is to determine whether Co serum and blood levels correlate with the synovial fluid level. Beside this, the synovial fluid Co from patients without prosthesis has also been measured. Co has been determined in 54 samples (32 unilateral MoM and 22 controls) with inductively coupled plasma mass spectrometry in the three matrices. In the prosthesized group, cobalt was significantly higher compared with controls and in the synovial fluid it strongly correlated with whole blood Co (p?=?0.847) and serum (p?=?0.855). Moreover, the Co levels into whole blood and serum were significantly different. In conclusion, haematic Co concentration correctly reflects Co local level.     

Nonlinear fractal dynamics of human colonic pressure activity based upon the box-counting method

The computational fractal dimension of human colonic pressure activity acquired by a telemetric capsule robot under normal physiological conditions was studied using the box-counting method. The fractal dimension is a numeric value that quantifies to measure how rough the signal is from nonlinear dynamics, rather than its amplitude or other linear statistical features. The colonic pressure activities from the healthy subject during three typical periods were analysed. The results showed that the activity might be fractal with a non-integer fractal dimension after it being integrated over time using the cumsum method, which was never revealed before. Moreover, the activity (after it being integrated) acquired soon after wakening up was the roughest (also the most complex one) with the largest fractal dimension, closely followed by that acquired during sleep with that acquired long time after awakening up (in the daytime) ranking third with the smallest fractal dimension. Fractal estimation might provide a new method to learn the nonlinear dynamics of human gastrointestinal pressure recordings.     

肠道菌群失调与肝硬化伴SBP患者疾病发展的关系及三联活菌胶囊干预性研究

目的分析肠道菌群失调与肝硬化伴自发性细菌性腹膜炎(SBP)患者疾病发展的关系及三联活菌胶囊的应用价值。方法将我院2017年1月至2019年12月间收治的94例肝硬化伴SBP患者作为观察组研究对象,50例健康者作为本研究对照组,将观察组患者依照随机信封法分为B组及A组,B组采用三联活菌胶囊治疗,A组采用常规方案治疗。采用16S rDNA测序技术检测患者肠道菌群种类和多样性。结果观察组患者诺卡氏菌科、盐单胞菌科、肠杆菌科、链球菌科、韦荣球菌科丰度均高于对照组,拟杆菌科、普雷沃菌科、毛螺菌科均低于对照组,OTUs、Chao、Shannon指数明显低于对照组。肠道菌群种类、OTUs、Chao、Shannon指数是影响肝硬化伴SBP患者疾病发展的影响因素,以上差异均就有统计学意义(P0.05)。治疗后B组患者肠道菌群OTUs、Chao和Shannon明显高于对照组,差异均具有统计学意义(P0.05)。结论肠道菌群失调是影响肝硬化伴SBP患者疾病发展的独立影响因素,采用三联活菌胶囊干预可有效纠正患者体内肠道菌群失调。